MDPI’s Journal Cluster of Pharmaceutical Science

Pharmaceutical science is a dynamic and multidisciplinary field focused on the development, formulation, and manufacture of medicines and other pharmaceutical products. It encompasses a wide range of areas, including drug discovery and development, analytical methods, quality control, pharmacology, toxicology, and drug delivery systems. By integrating expertise across research and development, quality assurance, validation, and manufacturing, pharmaceutical science seeks to address critical challenges in medicine and improve health outcomes worldwide.

MDPI’s pharmaceutical science cluster serves as a vibrant hub for cutting-edge research, fostering a deep and comprehensive understanding of the vital role pharmaceuticals play in modern healthcare. Our mission goes beyond publishing; we aim to accelerate the dissemination of discoveries that drive innovation in drug development and pharmaceutical research. This cluster offers authors a variety of publishing opportunities, ensuring that the work of academics reaches the most relevant audiences and generates the greatest impact within the diverse landscape of pharmaceutical science.

Journal Cluster Overview

Scientia Pharmaceutica (ISSN: 2218-0532) focuses on advancing pharmaceutical sciences and related disciplines, with special emphasis on medicinal and pharmaceutical chemistry, pharmacognosy and pharmaceutical biology, pharmacology, and pharmaceutical technology, while also encompassing pharmacy didactics, pharmaeconomy, nutritional sciences, and contributions to pharmacopeia monographs. Scientia Pharmaceutica is led by Editor-in-Chief Prof. Dr. Helmut Viernstein (Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Austria). The journal is owned by the Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).

Marine Drugs (ISSN 1660-3397) focuses on the discovery, development, exploitation, and production of biologically and therapeutically active compounds from marine habitats. Marine Drugs is led by Editor-in-Chief Prof. Dr. Bill J. Baker (Department of Chemistry, University of South Florida, USA).

Pharmaceuticals (ISSN: 1424-8247) focuses on the multidisciplinary aspects of drug discovery and development, with special emphasis on small molecule drug candidates, therapeutic biomolecules and natural products, biological targets and biomarkers, radiopharmaceutical sciences and imaging, and pharmacokinetics and pharmacodynamics, as well as pharmaceutical preparations and drug delivery strategies. Pharmaceuticals is led by Editor-in-Chief Prof. Dr. Amélia Pilar Rauter (Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Universidade de Lisboa, Portugal).

Pharmaceutics (ISSN: 1999-4923) focuses on the science and technology of pharmaceutics and biopharmaceutics, with special emphasis on pharmaceutical formulation, process development, drug delivery systems, pharmacokinetics, biopharmaceutics, pharmacogenetics, and interdisciplinary research integrating engineering, biomedical sciences, and cell biology, while uniquely encouraging the submission of research proposals, ideas, and studies funded by public sources, with full experimental detail provision for reproducibility. Pharmaceutics is led by Editor-in-Chief Prof. Dr. Patrick J. Sinko (Department of Pharmaceutics, Rutgers University, USA).

Pharmacy (ISSN: 2226-4787) focuses on pharmacy education and practice, emphasizing competency-based training, curriculum innovation, diverse practice settings, pharmaceutical care, patient-centric initiatives, workforce trends, and the integration of technology, economics, and policy in pharmacy. Pharmacy is led by Editor-in-Chief Prof. Dr. Jon Schommer (College of Pharmacy, University of Minnesota, USA).

Future Pharmacology (ISSN: 2673-9879) focuses on basic and clinical pharmacology, drug discovery, and therapeutics, with special emphasis on drug design, metabolism, biochemical, cellular, and molecular pharmacology, drug interactions, neuropharmacology, psychopharmacology, drug misuse/addiction, behavioral pharmacology, toxicology, pharmacogenetics, and biopharmaceuticals. Future Pharmacology is led by Editor-in-Chief Prof. Dr. Fabrizio Schifano (Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire, UK).

Pharmacoepidemiology (ISSN: 2813-0618) focuses on pharmacoepidemiological studies, including methodological advances, pharmacovigilance, prescription practices, pharmacoeconomics, and clinical applications or regulatory guidelines of pharmaceuticals and medical devices. Pharmacoepidemiology is led by Editor-in-Chief Dr. Carlotta Franchi (Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy).

Drugs and Drug Candidates (ISSN: 2813-2998) focuses on the development lifecycle of therapeutic agents, with special emphasis on chemistry-driven approaches, virtual design/screening (molecular docking, AI), synthesis methodologies, in vitro/in vivo evaluations, drug delivery, intellectual property, regulatory affairs, and market analysis for marketed and investigational drugs. Drugs and Drug Candidates is led by Editor-in-Chief Dr. Jean Jacques Vanden Eynde (Department of Organic Chemistry (FS), University of Mons-UMONS, Belgium).

Journal of Pharmaceutical and BioTech Industry (ISSN: 2813-9380) focuses on applied and translational research within the pharmaceutical and biotechnology sectors to enhance patient wellbeing, with special emphasis on drug discovery, development, delivery, manufacturing, and fostering interdisciplinary collaboration among academia, industry, and regulatory agencies. Journal of Pharmaceutical and BioTech Industry is led by Editor-in-Chief Prof. Dr. Bozena B. Michniak-Kohn (Department of Pharmaceutics, The State University of New Jersey, USA; Center for Dermal Research, The State University of New Jersey, USA).

Journals	Launch Year	Impact Factor (2023)	CiteScore	First Decision (median)	Acceptance to Publication (median)	APC
	1933	2.3	4.6	26.1 Days	5.3 Days	CHF 1000
	2003	4.9	10.1	13.3 Days	2.4 Days	CHF 2900
	2004	4.3	6.1	13.9 Days	3.4 Days	CHF 2900
	2009	4.9	7.9	15.5 Days	2.9 Days	CHF 2900
	2013	2.0	-	24.6 Days	3.3 Days	CHF 1800
	2021	-	-	19.2 Days	3.7 Days	CHF 1000
	2022	-	-	29.5 Days	4.7 Days	CHF 1000
	2022	-	-	25.7 Days	3.8 Days	CHF 1000
	2024	-	-	18 Days	4 Days	CHF 1000

MDPI’s Mission and Values:

As a pioneer of academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms across all disciplines. MDPI’s guidelines for disseminating open science are based on the following values and guiding principles:

Open Access: All of our content is published in open access and distributed under a Creative Commons License, providing free access to science and the latest research, allowing articles to be freely shared and content to be re-used with proper attribution;
Timeliness and Efficiency: Publishing the latest research through thorough editorial work, ensuring a first decision is provided to authors in under 32 days and papers are published within 7-10 days upon acceptance;
Simplicity: Offering user-friendly tools and services in one place to enhance the efficiency of our editorial process;
High-Quality Service: Supporting scholars and their work by providing a range of options such as journal publication at mdpi.com, early publication at preprints.org, and conferences on sciforum.net to make a positive impact on research;
Flexibility: Adapting and developing new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
Rooted in Sustainability: Ensuring the long-term preservation of published papers and supporting the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open science practices.

Selected Topics and Special Issues: